76 related articles for article (PubMed ID: 25781574)
1. Lung cancer: Driver-mutation-dependent stratification: learning from STAT3.
Errico A
Nat Rev Clin Oncol; 2015 May; 12(5):251. PubMed ID: 25781574
[No Abstract] [Full Text] [Related]
2. Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis.
Grabner B; Schramek D; Mueller KM; Moll HP; Svinka J; Hoffmann T; Bauer E; Blaas L; Hruschka N; Zboray K; Stiedl P; Nivarthi H; Bogner E; Gruber W; Mohr T; Zwick RH; Kenner L; Poli V; Aberger F; Stoiber D; Egger G; Esterbauer H; Zuber J; Moriggl R; Eferl R; Győrffy B; Penninger JM; Popper H; Casanova E
Nat Commun; 2015 Mar; 6():6285. PubMed ID: 25734337
[TBL] [Abstract][Full Text] [Related]
3. STAT3 is a master regulator of epithelial identity and KRAS-driven tumorigenesis.
D'Amico S; Shi J; Martin BL; Crawford HC; Petrenko O; Reich NC
Genes Dev; 2018 Sep; 32(17-18):1175-1187. PubMed ID: 30135074
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-6 Prevents the Initiation but Enhances the Progression of Lung Cancer.
Qu Z; Sun F; Zhou J; Li L; Shapiro SD; Xiao G
Cancer Res; 2015 Aug; 75(16):3209-15. PubMed ID: 26122841
[TBL] [Abstract][Full Text] [Related]
5. Regulation of metastases by signal transducer and activator of transcription 3 signaling pathway: clinical implications.
Huang S
Clin Cancer Res; 2007 Mar; 13(5):1362-6. PubMed ID: 17332277
[TBL] [Abstract][Full Text] [Related]
6. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
[TBL] [Abstract][Full Text] [Related]
7. Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma.
Bronte G; Rizzo S; La Paglia L; Adamo V; Siragusa S; Ficorella C; Santini D; Bazan V; Colucci G; Gebbia N; Russo A
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S21-9. PubMed ID: 21129606
[TBL] [Abstract][Full Text] [Related]
8. The oncogenic effects of constitutive Stat3 signaling in salivary gland cancer cells are mediated by survivin and modulated by the NSAID sulindac.
Nikitakis NG; Scheper MA; Papanikolaou VS; Sauk JJ
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 Jun; 107(6):826-36. PubMed ID: 19272804
[TBL] [Abstract][Full Text] [Related]
9. Differential expression and activation of epidermal growth factor receptor 1 (EGFR1), ERK, AKT, STAT3, and TWIST1 in nonsmall cell lung cancer (NSCLC).
Gorgisen G; Ozes D; Pehlivanoglu S; Erdogan A; Dertsiz L; Ozbilim G; Ozbudak IH; Savas B; Ozes ON
Exp Lung Res; 2013 Nov; 39(9):387-98. PubMed ID: 24117170
[TBL] [Abstract][Full Text] [Related]
10. Growth inhibition of KRAS‑ and EGFR‑mutant lung adenocarcinoma by cosuppression of STAT3 and the SRC/ARHGAP35 axis.
Onodera K; Sakurada A; Notsuda H; Watanabe T; Matsuda Y; Noda M; Endo C; Okada Y
Oncol Rep; 2018 Sep; 40(3):1761-1768. PubMed ID: 30015929
[TBL] [Abstract][Full Text] [Related]
11. [CDK4, a specific target in the treatment of lung adenocarcinomas mutated for KRAS].
Dubus P
Med Sci (Paris); 2010 Dec; 26(12):1023-5. PubMed ID: 21187034
[No Abstract] [Full Text] [Related]
12. Targeting the Ras-ERK pathway in pancreatic adenocarcinoma.
Neuzillet C; Hammel P; Tijeras-Raballand A; Couvelard A; Raymond E
Cancer Metastasis Rev; 2013 Jun; 32(1-2):147-62. PubMed ID: 23085856
[TBL] [Abstract][Full Text] [Related]
13. Lysine methylation in cancer: SMYD3-MAP3K2 teaches us new lessons in the Ras-ERK pathway.
Colón-Bolea P; Crespo P
Bioessays; 2014 Dec; 36(12):1162-9. PubMed ID: 25382779
[TBL] [Abstract][Full Text] [Related]
14. A sesquiterpene lactone antrocin from Antrodia camphorata negatively modulates JAK2/STAT3 signaling via microRNA let-7c and induces apoptosis in lung cancer cells.
Yeh CT; Huang WC; Rao YK; Ye M; Lee WH; Wang LS; Tzeng DT; Wu CH; Shieh YS; Huang CY; Chen YJ; Hsiao M; Wu AT; Yang Z; Tzeng YM
Carcinogenesis; 2013 Dec; 34(12):2918-28. PubMed ID: 23880305
[TBL] [Abstract][Full Text] [Related]
15. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
[TBL] [Abstract][Full Text] [Related]
16. IL6 Trans-signaling Promotes KRAS-Driven Lung Carcinogenesis.
Brooks GD; McLeod L; Alhayyani S; Miller A; Russell PA; Ferlin W; Rose-John S; Ruwanpura S; Jenkins BJ
Cancer Res; 2016 Feb; 76(4):866-76. PubMed ID: 26744530
[TBL] [Abstract][Full Text] [Related]
17. Favorable response to erlotinib in a lung adenocarcinoma with both epidermal growth factor receptor exon 19 deletion and K-ras G13D mutations.
Lee CN; Chen HY; Liu HE
J Clin Oncol; 2010 Mar; 28(7):e111-2. PubMed ID: 20008635
[No Abstract] [Full Text] [Related]
18. Peroxiredoxin II Is Essential for Maintaining Stemness by Redox Regulation in Liver Cancer Cells.
Kwon T; Bak Y; Park YH; Jang GB; Nam JS; Yoo JE; Park YN; Bak IS; Kim JM; Yoon DY; Yu DY
Stem Cells; 2016 May; 34(5):1188-97. PubMed ID: 26866938
[TBL] [Abstract][Full Text] [Related]
19. Multiple pathways regulate Cten in colorectal cancer without a Tensin switch.
Thorpe H; Akhlaq M; Jackson D; Al Ghamdi S; Storr S; Martin S; Ilyas M
Int J Exp Pathol; 2015 Dec; 96(6):362-9. PubMed ID: 26852686
[TBL] [Abstract][Full Text] [Related]
20. Physalin A exerts anti-tumor activity in non-small cell lung cancer cell lines by suppressing JAK/STAT3 signaling.
Zhu F; Dai C; Fu Y; Loo JF; Xia D; Gao SP; Ma Z; Chen Z
Oncotarget; 2016 Feb; 7(8):9462-76. PubMed ID: 26843613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
